Daily non-political popular news in brief.

Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma

Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells.

Read more »

Keywords: mayo, clinic, cancer, center, researcher, mold, by-product, kills, multiple, myeloma, product, kill

« Previous | Next »

Similar news on "Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma":

1. Investigating the measles virus as a tool to kill multiple myeloma
   03-05-2007 · EurekAlert!
   Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure.
   Similar news · Read more »
   
2. Mayo Clinic -- Collaborating to move treatment research forward
   12-12-2006 · EurekAlert!
   Novel therapies are greatly improving the long-term outlook for patients with multiple myeloma, say researchers at Mayo Clinic Cancer Center, who have led efforts in testing these treatments and moving them quickly into first-line therapies.
   Similar news · Read more »
   
3. Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
   12-10-2006 · EurekAlert!
   Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.
   Similar news · Read more »
   
4. Multiple myeloma clinical trial closes early
   04-04-2007 · EurekAlert!
   Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.
   Similar news · Read more »
   
5. New therapeutic options for newly diagnosed multiple myeloma patients
   12-10-2007 · EurekAlert!
   Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy.
   Similar news · Read more »
   
6. Use of mammograms in men is rising, but Mayo Clinic researchers find little reason to administer
   12-16-2006 · EurekAlert!
   Many men have breast symptoms, including enlarged or painful breast tissue, but the majority do not need a mammogram, say researchers from Mayo Clinic Cancer Center. Mammograms are used to check for the presence of breast cancers, which are very rare in males.
   Similar news · Read more »
   
7. Drug combination slows progression of treatment resistant bone marrow cancer
   12-12-2006 · EurekAlert!
   Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.
   Similar news · Read more »
   
8. Octogenarians are not too old for cancer surgery
   11-27-2006 · EurekAlert!
   Mayo Clinic Cancer Center researchers have found that a radical prostatectomy can be a viable option for select octogenarian patients. The findings, which run counter the conventional practice of generally avoiding surgeries for individuals over 80 years old solely based on age, are available today in Urology.
   Similar news · Read more »
   
9. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
   10-30-2006 · EurekAlert!
   Mayo Clinic Cancer Center has opened a new clinical study using a vaccine strain of the measles virus to attack recurrent glioblastoma multiforme, a largely untreatable brain tumor.
   Similar news · Read more »
   
10. Mayo Clinic Cancer Center -- Working on the tough cases
    12-11-2006 · EurekAlert!
    Mayo Clinic Cancer Center, in collaboration with researchers from the University of Iowa, today presented results of a Phase II clinical study indicating that an oral drug, tipifarnib, can stall or reverse disease progression for patients with relapsed aggressive non-Hodgkin lymphoma.
    Similar news · Read more »